Key result
Enoxaparin 3,000 IU twice daily reduced venous thromboembolism risk but increased major bleeding compared to 4,000 IU once daily in major orthopaedic surgery.
Why the study?
Does enoxaparin 3,000 IU twice daily compared to 4,000 IU once daily improve efficacy and safety in patients undergoing major orthopaedic surgery?
Meta-Analysis (n=56,423)
Does enoxaparin 3,000 IU twice daily compared to 4,000 IU once daily improve efficacy and safety in patients undergoing major orthopaedic surgery?
In major orthopaedic surgery, enoxaparin 3,000 IU twice daily provides greater efficacy against venous thromboembolism but carries a higher risk of major bleeding compared to the 4,000 IU once daily regimen.
Answers are grounded in this paper and cite their sources.
Supports once-daily 4,000 IU dosing to limit major bleeding in orthopaedic surgery despite reduced VTE efficacy; extends LMWH regimen comparisons.
Two enoxaparin dosage regimens are used as comparators to evaluate new anticoagulants for thromboprophylaxis in patients undergoing major orthopaedic surgery, but so far no satisfactory direct comparison between them has been published. Our objective was to compare the efficacy and safety of enoxaparin 3,000 anti-Xa IU twice daily and enoxaparin 4,000 anti-Xa IU once daily in this clinical setting by indirect comparison meta-analysis, using Bucher's method. We selected randomised controlled trials comparing another anticoagulant, placebo (or no treatment) with either enoxaparin regimen for venous thromboembolism prophylaxis after hip or knee replacement or hip fracture surgery, provided that the second regimen was assessed elsewhere versus the same comparator. Two authors independently evaluated study eligibility, extracted the data, and assessed the risk of bias. The primary efficacy outcome was the incidence of venous thomboembolism. The main safety outcome was the incidence of major bleeding. Overall, 44 randomised comparisons in 56,423 patients were selected, 35 being double-blind (54,117 patients). Compared with enoxaparin 4,000 anti-Xa IU once daily, enoxaparin 3,000 anti-Xa IU twice daily was associated with a reduced risk of venous thromboembolism (relative risk [RR]: 0.53, 95% confidence interval [CI]: 0.40 to 0.69), but an increased risk of major bleeding (RR: 2.01, 95% CI: 1.23 to 3.29). In conclusion, when interpreting the benefit-risk ratio of new anticoagulant drugs versus enoxaparin for thromboprophylaxis after major orthopaedic surgery, the apparently greater efficacy but higher bleeding risk of the twice-daily 3,000 anti-Xa IU enoxaparin regimen compared to the once-daily 4,000 anti-Xa IU regimen should be taken into account.
No takes yet. Share an insight, caveat, or question.
Chapelle et al. (2014) conducted a meta-analysis in major orthopaedic surgery (n=56,423). Enoxaparin vs. Enoxaparin 4,000 anti-Xa IU once daily was evaluated on incidence of venous thomboembolism (RR 0.53, 95% CI 0.40 to 0.69). Enoxaparin 3,000 IU twice daily reduced venous thromboembolism risk but increased major bleeding compared to 4,000 IU once daily in major orthopaedic surgery.
Synapse has enriched 10 related papers. Consider them for comparative context: